Pricing Log in Create free account
Saturday 17 October 2026 Export DHR’s income statement to Excel — free account

Danaher Corporation

DHR Healthcare Diagnostics & Research

Danaher Corporation’s revenue for fiscal 2025 (year ended December 2025) was $24.6 billion, up 2.90% from fiscal 2024. In the quarter to June 2026, revenue grew 5.54%, EPS grew 59.7%, free cash flow grew 15.6% and total debt rose 49.2%, each against the same quarter a year earlier. Member of the S&P 500.

228.97 2.53 −1.09%
Market cap
$162.7B
P/E
40.5×
Fwd P/E
29.2×
Dividend yield
0.66%
F-score
6/9
Altman Z
4.52
Beneish M
−2.57
Dividend safety
69/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Danaher Corporation (DHR) Business Profile

Updated before January 2025

Company Overview

Danaher Corporation (NYSE: DHR) is a globally diversified conglomerate headquartered in Washington, D.C., United States. Founded in 1984 by brothers Steven and Mitchell Rales, the company initially focused on manufacturing industrial tools and equipment. Over the years, Danaher has evolved into a leading science and technology innovator, specializing in life sciences, diagnostics, environmental, and applied solutions. The company operates in more than 60 countries and employs over 80,000 people worldwide.

Danaher’s leadership team is spearheaded by Rainer M. Blair, who serves as the President and Chief Executive Officer. Blair has been instrumental in driving the company’s growth and innovation strategies. The company’s board of directors and executive leadership team bring a wealth of experience from various industries, ensuring Danaher remains at the forefront of technological advancements and operational excellence.

Core Business Segments

Danaher operates through three primary business segments, each offering a diverse range of products and services:

1. Life Sciences

This segment focuses on providing tools and technologies that enable scientific research and discovery. Key offerings include:

  • Mass Spectrometry and Chromatography Systems: Used in pharmaceutical research and development.
  • Genomics and Cellular Analysis Tools: Products like flow cytometers and gene sequencing technologies.
  • Bioprocessing Solutions: Equipment and consumables for biologic drug production.

Notable brands under this segment include Cytiva, Beckman Coulter Life Sciences, and Pall Corporation.

2. Diagnostics

The Diagnostics segment delivers solutions that improve patient care and healthcare efficiency. Key products include:

  • Clinical Diagnostic Instruments: Blood analyzers, immunoassay systems, and molecular diagnostic tools.
  • Point-of-Care Testing Devices: Portable diagnostic tools for rapid testing.
  • Lab Automation Systems: Streamlining laboratory workflows.

Prominent brands in this segment include Cepheid, Leica Biosystems, and Radiometer.

3. Environmental & Applied Solutions

This segment addresses global challenges related to water quality, food safety, and environmental sustainability. Key offerings include:

  • Water Quality Testing and Treatment Solutions: Instruments for water analysis and purification.
  • Product Identification Systems: Coding, marking, and labeling solutions for industrial applications.
  • Environmental Monitoring Tools: Devices for air quality and environmental compliance.

Leading brands in this segment include Hach, Trojan Technologies, and Videojet.

Business Model

Danaher’s business model is built on the Danaher Business System (DBS), a proprietary framework that emphasizes continuous improvement, operational efficiency, and customer-centric innovation. The DBS approach integrates lean manufacturing principles, rigorous performance metrics, and a culture of collaboration to drive growth and profitability.

Revenue generation is primarily achieved through the sale of high-value instruments, consumables, and software solutions. Danaher also offers recurring revenue streams through service contracts, maintenance, and subscription-based software offerings. The company’s focus on innovation and strategic acquisitions has enabled it to expand its product portfolio and enter new markets.

Strategic Direction

Danaher’s strategic priorities include:

  • Innovation and R&D: Investing heavily in research and development to introduce cutting-edge technologies and solutions.
  • Sustainability Goals: Committed to reducing its environmental footprint by improving energy efficiency, minimizing waste, and developing sustainable products.
  • Expansion into Emerging Markets: Targeting high-growth regions such as Asia-Pacific and Latin America to capture new opportunities.
  • Digital Transformation: Leveraging data analytics, artificial intelligence, and IoT to enhance product performance and customer experience.
  • Strategic Acquisitions: Continuously acquiring companies that align with its core business segments to strengthen its market position.

Competitive Landscape

Danaher operates in highly competitive markets and faces competition from both large multinational corporations and specialized niche players. Key competitors include:

  • Thermo Fisher Scientific: Competes in life sciences and diagnostics.
  • Agilent Technologies: Focuses on analytical instruments and lab solutions.
  • PerkinElmer: Offers similar products in diagnostics and environmental solutions.
  • Waters Corporation: Specializes in chromatography and mass spectrometry.
  • GE Healthcare: Competes in medical imaging and life sciences.

Despite the competition, Danaher’s diversified portfolio, strong brand reputation, and operational excellence give it a competitive edge.

Risk Factors

Danaher faces several risks that could impact its business operations and financial performance:

  • Market Dependence: Heavy reliance on the healthcare and life sciences sectors makes the company vulnerable to changes in government regulations and healthcare spending.
  • Supply Chain Disruptions: Global supply chain challenges, including raw material shortages and transportation delays, could affect production and delivery timelines.
  • Economic Uncertainty: Fluctuations in global economic conditions may impact customer spending and investment in new technologies.
  • Technological Obsolescence: Rapid advancements in technology require continuous innovation to stay competitive.
  • Regulatory Compliance: Operating in highly regulated industries exposes the company to compliance risks and potential legal liabilities.

Recent Developments

Danaher has made significant strides in recent years, including:

  • Acquisition of Aldevron: Strengthening its position in the genomic medicine space by acquiring Aldevron, a leading provider of plasmid DNA and mRNA manufacturing services.
  • Expansion of Digital Solutions: Launching new software platforms and digital tools to enhance customer experience and operational efficiency.
  • COVID-19 Response: Developing diagnostic tests and bioprocessing solutions to support global efforts against the pandemic.
  • Sustainability Initiatives: Implementing energy-efficient practices and launching eco-friendly products to meet sustainability goals.

Investment Considerations

Strengths:

  • Diversified portfolio across high-growth industries.
  • Strong financial performance and consistent revenue growth.
  • Proven track record of successful acquisitions and integrations.
  • Robust innovation pipeline and commitment to R&D.
  • Global presence with a focus on emerging markets.

Risks:

  • Exposure to regulatory and compliance risks.
  • Dependence on key markets and industries.
  • Potential impact of economic downturns and geopolitical tensions.

Conclusion

Danaher Corporation is a global leader in science and technology, with a strong presence in life sciences, diagnostics, and environmental solutions. The company’s commitment to innovation, operational excellence, and sustainability positions it for long-term growth. While it faces challenges such as regulatory risks and supply chain disruptions, its diversified portfolio and strategic initiatives make it a compelling choice for investors seeking exposure to high-growth industries.